Thomas K. Jones

Thomas K. Jones

Auto-generated profile, based on publicly available information

Thomas K. Jones

Seattle Children’s Hospital, WA (T.K.J.).

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in JACC
Verified
Journal Article
Closed access
TJThomas K. Jones
Thomas K. Jones
LLLarry A. Latson
Larry A. Latson
EZEvan Zahn
Evan Zahn
CFCraig E. Fleishman
Craig E. Fleishman
JJJoth Jacobson
Joth Jacobson
KKKirk Kanter
Kirk Kanter

1 January 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
TJThomas K. Jones
Thomas K. Jones
DMDoff B. McElhinney
Doff B. McElhinney
JVJulie A. Vincent
Julie A. Vincent
WHWilliam E. Hellenbrand
William E. Hellenbrand
JCJohn P. Cheatham
John P. Cheatham
LBLisa J. Bergersen
Lisa J. Bergersen
Background: The Melody valve was developed to extend the useful life of previously implanted right ventricular outflow tract (RVOT) conduits or bioprosthetic pulmonary valves, while preserving RV function and reducing the lifetime burden of surgery for patients with complex congenital heart disease. Methods: Enrollment for the US Investigational Device Exemption study of the Melody valve began in 2007. Extended follow-up was completed in 2020. The primary outcome was freedom from transcatheter pulmonary valve (TPV) dysfunction (freedom from reoperation, reintervention, moderate or severe pulmonary regurgitation, and/or mean RVOT gradient >40 mm Hg). Secondary end points included stent fracture, catheter reintervention, surgical conduit replacement, and death. Results: One hundred seventy-one subjects with RVOT conduit or bioprosthetic pulmonary valve dysfunction were enrolled. One hundred fifty underwent Melody TPV replacement. Median age was 19 years (Q1–Q3: 15–26). Median discharge mean RVOT Doppler gradient was 17 mm Hg (Q1–Q3: 12–22). The 149 patients implanted >24 hours were followed for a median of 8.4 years (Q1–Q3: 5.4–10.1). At 10 years, estimated freedom from mortality was 90%, from reoperation 79%, and from any reintervention 60%. Ten-year freedom from TPV dysfunction was 53% and was significantly shorter in children than in adults. Estimated freedom from TPV-related endocarditis was 81% at 10 years (95% CI, 69%–89%), with an annualized rate of 2.0% per patient-year. Conclusions: Ten-year outcomes from the Melody Investigational Device Exemption trial affirm the benefits of Melody TPV replacement in the lifetime management of patients with RVOT conduits and bioprosthetic pulmonary valves by providing sustained symptomatic and hemodynamic improvement in the majority of patients. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00740870.

21 September 2016 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
PSPatrick M. Sullivan
Patrick M. Sullivan
ARAgustin E. Rubio
Agustin E. Rubio
TJTroy A. Johnston
Troy A. Johnston
TJThomas K. Jones
Thomas K. Jones

16 July 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
BMBrian H. Morray
Brian H. Morray
MGMatthew J. Gillespie
Matthew J. Gillespie
JCJohn P. Cheatham
John P. Cheatham
ASArash Salavitabar
Arash Salavitabar
LPLynn Peng
Lynn Peng
DMDoff B. McElhinney
Doff B. McElhinney
BACKGROUND: The Harmony transcatheter pulmonary valve (TPV) is designed to treat severe pulmonary regurgitation in the native or surgically repaired right ventricular (RV) outflow tract. Early outcomes after TPV replacement with the Harmony valve have been positive, but longer-term data are limited. METHODS: The study included patients who received a commercially available TPV22 or TPV25 device as part of the nonrandomized, prospective Native Outflow Tract Early Feasibility Study, Harmony Pivotal Trial, and Continued Access Study. Patients completed at least 3 years of follow-up, and outcomes to 5 years were reported when available. RESULTS: Eighty-nine patients were catheterized, and 86 were successfully implanted with a Harmony TPV. Median duration of follow-up was 5 (range 0–6) years in the TPV22 group and 3 (1–4) years in the TPV25 group. At 3 years, all patients with a TPV22 and 96% of those with a TPV25 had ≤mild pulmonary regurgitation. By magnetic resonance imaging, significant improvements from preimplant to 2 years were observed in RV end-diastolic volume index, RV to left ventricular end-diastolic volume ratio, and effective RV stroke volume (all P <0.001). SF-36 quality-of-life scores improved after Harmony implantation and were sustained over 3 years. Early cases of ventricular tachycardia resolved, and there were no new arrhythmias. Adverse events up to 5 years included 3 deaths unrelated to the device or procedure, 2 cases of endocarditis that were treated (1 medically, 1 transcatheter debulking of a vegetation) and resolved, 6 patients with RV outflow tract obstruction and thrombosis resulting in valve-in valve procedures, and 1 major stent fracture resulting in surgical explant. CONCLUSIONS: At 3 to 5 years, Harmony TPV replacement resulted in sustained valve competence, beneficial cardiac remodeling, and improved quality of life. Continued monitoring is needed to assess long-term outcomes and valve performance. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01762124; NCT02979587.

2 April 2004 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
KCK. M. Carlson
K. M. Carlson
TJT. A. Johnston
T. A. Johnston
TJT. K. Jones
T. K. Jones
RGR. G. Grifka
R. G. Grifka

1 January 2017 in The Annals of Thoracic Surgery
Verified
Journal Article
Open access
PDF file
CBCastigliano M. Bhamidipati
Castigliano M. Bhamidipati
JMJames M. McCabe
James M. McCabe
TJThomas K. Jones
Thomas K. Jones
WLWilliam L. Lombardi
William L. Lombardi
MRMark Reisman
Mark Reisman
JPJay D. Pal
Jay D. Pal
Dr Pal discloses a financial relationship with Heartware Inc and St. Jude Medical Corp. A 29-year-old man with mosaic vasculopathy had an asymptomatic 32 × 30-mm distal left main coronary artery aneurysm (CAA). He had no tobacco history, Kawasaki disease, atherosclerosis, or other risk factors for CAA. Both the left anterior descending (LAD) and circumflex artery (CXA) originated at the base of this aneurysm (Figs 1A, 1B). Hybrid repair was undertaken because of difficulty in ligating the aneurysm at the distal CXA origin. A 5 × 50-mm Viabahn stent graft (Gore and Associates, Newark, DE) from the left main to the mid CXA at the neck distal to the aneurysm was deployed. A 6 × 16 iCast Atrium stent graft (Hudson, NH) was positioned to overlap the proximal stent into left main CAA (Fig 1C). Completion angiography demonstrated exclusion of aneurysm with TIMI-3 flow into the CXA system. Left internal mammary artery to LAD coronary artery bypass grafting was completed, and the proximal LAD was ligated as it exited the aneurysm. Outpatient imaging showed a patent graft to the LAD and an open CXA system with aneurysmal exclusion (Fig 1D). Coronary aneurysms occur between 0.3% and 4.9% [ 1 Hartnell G.G. Parnell B.M. Pridie R.B. Coronary artery ectasia. Its prevalence and clinical significance in 4993 patients. Br Heart J. 1985; 54 : 392-395 Crossref PubMed Scopus (411) Google Scholar ]. A review of 16 publications in 17 patients showed CABG therapy use in 88% of patients with CAA [ 2 Harandi S. Johnston S.B. Wood R.E. Roberts W.C. Operative therapy of coronary arterial aneurysm. Am J Cardiol. 1999; 83 : 1290-1293 Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar ]. Neither has CAA in mosaicism, nor has hybrid management of such a giant CAA been reported (Fig 2, arrows). Fig 1 View Large Image Figure Viewer Download Hi-res image Download (PPT) Fig 2 View Large Image Figure Viewer Download Hi-res image Download (PPT)